Having trouble accessing articles? Reset your cache.

Halozyme jumps after FDA lifts hold on subcutaneous Cinryze

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.54 (24%) to $7.95 on Friday after it and partner ViroPharma Inc. (NASDAQ:VPHM)

Read the full 189 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE